Skip to content

Clinical trials

Phase 2/3 trials in Iran

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 2/3 Country / region: Iran Clear all

119 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20053
20063
20076
200810
200913
20105
20117
201212
20138
20143
20155
20166
20176
20187
20195
20206
20212
20224
20234
20242

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed64
Unknown status49
Recruiting2
Withdrawn2
Active, not recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Shahid Beheshti University of Medical Sciences24
Isfahan University of Medical Sciences23
Tehran University of Medical Sciences22
Shiraz University of Medical Sciences11
National Nutrition and Food Technology Institute7
Royan Institute6
Islamic Azad University, Sanandaj3
Mashhad University of Medical Sciences3
Mazandaran University of Medical Sciences3
Imam Khomeini Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
COVID-193
Coronary Artery Disease3
Diabetes Mellitus, Type 23
Graves Ophthalmopathy3
Myocardial Infarction3
Non-alcoholic Fatty Liver Disease3
beta-Thalassemia3
Acne Vulgaris2
Amyotrophic Lateral Sclerosis2
Angina, Stable2

Trials

Showing 26 to 50 of 119. Each trial links to its page on Pharma Observatory.

19 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.